McKesson has delivered four consecutive earnings beats and offers roughly 8.7% upside to its analyst consensus target with a favorable risk/reward of nearly 2-to-1, but business quality scores below the minimum acceptable threshold with no identifiable competitive moat, the stock is trading below its 200-day moving average with falling on-balance volume, and a put/call ratio of 2.06 signals heavy downside hedging — a combination that warrants caution despite the attractive price geometry.
Thesis pillars
- Quality Below Minimum Threshold↓Deteriorating
- Perfect Four Quarter Beat Streak↓Deteriorating
- Elevated Put Call Downside Hedging↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
McKesson Corporation (MCK) Stock Analysis
Range Bound setup
Healthcare · Medical Distribution
Sell if holding. Engine safety override at $862.70: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality; Negative price momentum.
McKesson distributes branded, generic, specialty, and OTC pharmaceuticals through four segments across the U.S. and Canada: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company runs 27 U.S.... Read more
Sell if holding. Engine safety override at $862.70: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Score 4.9/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news boost analyst 0.50, earnings proximity 81d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
About McKesson Corporation
About McKesson Corporation
McKesson Corporation distributes branded, generic, specialty, biosimilar, and OTC pharmaceuticals through 27 U.S. distribution centers and approximately 2,600 Canadian independent pharmacy franchises, competing directly with Cencora, Inc. and Cardinal Health, Inc. across North American pharmaceutical distribution. Four operating segments employed more than 43,000 people as of March 31, 2026 — roughly 38,000 in the U.S., 5,000 in Canada, and 400 internationally — making McKesson one of the largest pharmaceutical distributors in North America.
McKesson earns revenue through pharmaceutical wholesale to three primary U.S. channels: retail national accounts (chain pharmacies, mail-order, mass merchandisers), community pharmacies (including the Health Mart franchise network of approximately 3,900 locations), and institutional providers such as hospitals and integrated delivery networks. The Oncology & Multispecialty segment supports the U.S. Oncology Network, holds an 80% controlling interest in PRISM Vision for ophthalmology, and a 51% stake in Sarah Cannon Research Institute. The Prescription Technology Solutions segment connects more than 50,000 pharmacies and 1,000,000 providers to 650+ biopharma brands, helping patients access medicines more than 135 million times annually and save about $10 billion on medications. Generic sourcing is conducted through ClarusONE Sourcing Services LLP, a joint venture with Walmart Inc.
Show full overview
McKesson's most pronounced litigation exposure is its role as a defendant in opioid distribution cases brought by governmental entities — states, counties, and municipalities — and the company is subject to consent decrees issued by state courts governing controlled substance distribution. In April 2026, the company disclosed via Form 8-K the refinancing of credit facilities, entering a new revolving credit agreement with Bank of America as administrative agent while terminating the existing $1.0 billion 364-day and $4.0 billion five-year senior unsecured revolving credit facilities. The planned separation of Medical-Surgical Solutions into an independent publicly traded company — contingent on a favorable tax-free ruling, SEC registration effectiveness, Board approval, and regulatory clearances — adds execution complexity over the near term.
See also: Healthcare · Medical Distribution
From McKesson Corporation's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-08-15Recent Developments — McKesson Corporation
Latest news
- NEWS Wells Fargo Maintains Equal-Weight on McKesson, Raises Price Target to $933 — benzinga Aug 11, 2026 positive
- NEWS $1000 Invested In McKesson 5 Years Ago Would Be Worth This Much Today — benzinga Aug 7, 2026 positive
- NEWS TD Cowen Maintains Buy on McKesson, Raises Price Target to $1006 — benzinga Aug 6, 2026 positive
- NEWS UBS Maintains Buy on McKesson, Raises Price Target to $1080 — benzinga Aug 6, 2026 positive
- NEWS Evercore ISI Group Maintains Outperform on McKesson, Raises Price Target to $1000 — benzinga Aug 6, 2026 positive
Generated 2026-08-15T13:12:18Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-28Item 1.02MEDIUMMcKesson terminated its existing $1.0B 364-day and $4.0B five-year senior unsecured revolving credit facilities, both replaced by a new revolving credit agreement entered April 24, 2026, with Bank of America, N.A. as administrative agent.SEC filing →
- 2026-04-28Item 1.01LOWMcKesson entered a new Credit Agreement on April 24, 2026 with Bank of America, N.A. as administrative agent, replacing the existing $1.0B 364-day (maturing May 2026) and $4.0B five-year (maturing November 2029) senior unsecured revolving credit facilities.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $862.70: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Prior stop was $808.17. Score 4.9/10, moderate confidence.
Take-profit target: $892.26 (+2.7% upside). Prior stop was $808.17. Stop-loss: $808.17.
Target reached (2.7% upside); Quality below floor (3.5 < 4.0); Value-trap signals (3/5): Margin compression (op margin -15.5%), Material insider selling (24 sells, 0.04% of cap), Negative free cash flow.
McKesson Corporation trades at a P/E of 23.0 (forward 17.2). TrendMatrix value score: 5.8/10. Verdict: Sell.
23 analysts cover MCK with a consensus score of 4.3/5. Average price target: $991.
What does McKesson Corporation do?McKesson distributes branded, generic, specialty, and OTC pharmaceuticals through four segments across the U.S. and...
McKesson distributes branded, generic, specialty, and OTC pharmaceuticals through four segments across the U.S. and Canada: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company runs 27 U.S. distribution centers and roughly 2,600 Canadian pharmacy franchises, employing more than 43,000 people. It is separating Medical-Surgical Solutions into a standalone entity, with Apollo Funds acquiring a ~13% stake for $1.25 billion.